Thrombotic Microangiopathy Clinical Trial
Official title:
A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants With Thrombotic Microangiopathy (TMA) After Hematopoietic Stem Cell Transplantation (HSCT)
This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to < 18 years of age, with HSCT-TMA. The treatment period is 26 weeks, followed by a 26-week off-treatment follow-up period.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02604420 -
Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants
|
||
| Terminated |
NCT04743804 -
Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger
|
Phase 3 | |
| Recruiting |
NCT04845022 -
Incidence of Snakebite Associated Thrombotic Microangiopathy & Role of Peripheral Blood Smear as a Predictor of Clinical Outcome
|
||
| Terminated |
NCT00593229 -
International Registry and Biorepository for TMA(Thrombotic Microangiopathy)
|
N/A | |
| Recruiting |
NCT05991245 -
French National Cohort MATRIX "Renal and Systemic Thrombotic Microangiopathy"
|
||
| Terminated |
NCT00726544 -
Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy
|
Phase 2 | |
| Recruiting |
NCT04543591 -
Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant
|
Phase 3 | |
| Available |
NCT02355782 -
OMS721 Compassionate Use in Patients With Thrombotic Microangiopathy
|
N/A |